By Memorandum Opinion entered by The Honorable Gregory M. Sleet in Pfizer Inc. v. Sandoz Inc., et al., Civil Action No. 13-110-GMS (D.Del., Apr. 20, 2016), the Court denied defendants’ post-trial proposed finding that the Court find the patents-in-suit were invalid due to obviousness under 35 U.S.C. § 103. After having conducted a four-day bench trial in 2015 and considering the entire record in the case and the applicable law, the Court concluded that none of the asserted claims of the patents-in-suit were invalid due to obviousness and directed the Clerk of Court to enter final judgment in favor of the Plaintiffs. Id. at 1-19.
A copy of the Memorandum Opinion is attached.